

Press Release – October 2009, Baltimore, MD: CCC Diagnostics (CCCD) announces successful CMS HighMark Medicare Services and Maryland’s Medicaid enrollment, and the list of credentialing by national insurance companies for its Drug Response Indicator Test (DRIT). **DirectHit™ Test Panel for Breast Cancer** is a personalized clinical test service to select the optimal drug for each breast cancer patient. **Direct Hit™** is a trademark of CCC Diagnostics.

CCC Diagnostics, Inc (CCCD), a Baltimore-based pharmacodiagnosics Company, focused on establishing anti-cancer drug response predictions as guides for selection of effective chemotherapy treatments, announced today that Centers for Medicare & Medicaid has approved CCCD’s Medicare & Maryland’s Medicaid enrollment application and has issued the Provider Transaction Access Number (PTAN) for Drug Response Indicator Test (DRIT) trademarked as **DirectHit™ Test Panel for Breast Cancer**. DirectHit™ Test Panel for Breast Cancer is a diagnostic service for predicting treatment outcomes prior to the selection of anticancer drug therapy for individual patients, who have late stage breast cancer. This diagnostic service is designed to analyze an individual patient’s tumor in order to indicate its drug sensitivity or resistance to FDA-approved, National Comprehensive Cancer Network (NCCN) recommended chemotherapy drugs currently on the market. The service allows physicians to prescribe effective drugs and to exclude ineffective drug treatments, which optimizes use of the time window for treatment and reduces side effects, all resulting in prolonged patient survival and significant financial healthcare savings.

In addition to CMS HighMark Medicare Services and Maryland’s Medicaid Services approval, several additional insurance companies have recently credentialed the Company for reimbursement of this important diagnostic service. Insurance companies that have credentialed reimbursement are Care First BlueCross BlueShield - including all of the BC/BS Network, GIMSI Participating Provider Network, Selected Preferred Provider Network, Maryland Participating Provider Network, Preferred Provider Network and the WellPoint, Unicare and/or HealthLink Networks, which consist of American National Insurance Company, Assurant Health (Formerly Fortis Ins Co), Brokerage Concepts (Benefit Concepts), Colonial Healthcare, Coresource (A Trustmark Company), Destiny Health, Erin Group Administrators, FMH Benefit Services, Focus Healthcare Management, Group Benefit Services/Innovative Outsourcing, Guardian Life Insurance Company, IMA of Louisiana, Informed, Meritain Health (Formerly N. American -Admin), Multiplan (Affiliated NCCPPO Network),

The DirectHit™ Test Panel for Breast Cancer is the only predictive treatment outcome test service marketed for commonly prescribed comprehensive anti-breast cancer chemotherapy drugs. The test panel predicts the response of the individual tumor to the following drugs: taxanes and vinca alkaloids, antiestrogens, and 5-fluorouracil/capecitabine. Test panels for platinum salts, trastuzumab (Herceptin), and gemcitabine are currently being developed. The technology functions by measuring biomarkers expression linked to chemotherapy response, using fluorescence-labeled antibodies to assess biomarker expression.

CCCD is dedicated to “saving lives and life savings. In addition to its currently marketed breast cancer test, CCCD has ongoing research in personalized pharmaco diagnostic services for lung, colon, gastric, esophageal and pancreatic cancers. CCCD is a CLIA compliant testing medical laboratory licensed by the State of Maryland and is located at 3918 Vero Rd, Ste B, Baltimore, MD. The Company URL is www.cccddiag.com, and information on the test may be found at directhittest.com, and the telephone number is 410-633-4885.